Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Safety and Immunogenicity of SARS-CoV-2 S-2P Protein Vaccine MVC-COV1901 in People Living with HIV

Shu-Hsing Cheng, Chia En Lien, Szu-Min Hsieh, Chien-Yu Cheng, Wang-Da Liu, Ching-Lung Lo, Wen-Chien Ko, Yen-Hsu Chen, Ching-Tai Huang, Hsiao-Ting Chang, Shinn-Jang Hwang, Ning-Chi Wang, Ming-Che Liu, Yu-Lin Lee, I-Chen Tai, View ORCID ProfileJosue Antonio Garcia Estrada, Tzou-Yien Lin, Wen-Sen Lee
doi: https://doi.org/10.1101/2021.12.08.21267439
Shu-Hsing Cheng
aDepartment of Infectious Diseases, Taoyuan General Hospital, Ministry of Health and Welfare, Taoyuan, Taiwan
bSchool of Public Health, Taipei Medical University, Taipei, Taiwan
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chia En Lien
cMedigen Vaccine Biologics, Taipei, Taiwan
dInstitute of Public Health, College of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Szu-Min Hsieh
eDepartment of Internal Medicine, Division of Infectious Diseases, National Taiwan University Hospital, Taipei, Taiwan
fCollege of Medicine, National Taiwan University, Taipei, Taiwan
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chien-Yu Cheng
aDepartment of Infectious Diseases, Taoyuan General Hospital, Ministry of Health and Welfare, Taoyuan, Taiwan
gSchool of Public Health, National Yang Ming Chiao Tung University, Taipei, Taiwan
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wang-Da Liu
eDepartment of Internal Medicine, Division of Infectious Diseases, National Taiwan University Hospital, Taipei, Taiwan
hDepartment of Medicine, National Taiwan University Cancer Center, Taipei, Taiwan
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ching-Lung Lo
iDepartment of Internal Medicine, National Cheng Kung University Hospital, Tainan, Taiwan
jDepartment of Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wen-Chien Ko
iDepartment of Internal Medicine, National Cheng Kung University Hospital, Tainan, Taiwan
jDepartment of Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yen-Hsu Chen
kDepartment of Internal Medicine, Division of Infectious Diseases, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan
lSchool of Medicine, Graduate Institute of Medicine, Sepsis Research Centre, Centre of Tropical Medicine and Infectious Diseases, Kaohsiung Medical University, Kaohsiung, Taiwan
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ching-Tai Huang
mDepartment of Infectious Diseases, Chang Gung Memorial Hospital, Taoyuan, Taiwan
nCollege of Medicine, Chang Gung University, Taoyuan, Taiwan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hsiao-Ting Chang
oDepartment of Family Medicine, Taipei Veterans General Hospital
pSchool of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shinn-Jang Hwang
oDepartment of Family Medicine, Taipei Veterans General Hospital
pSchool of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ning-Chi Wang
qTri-Service General Hospital, Taipei, Taiwan
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ming-Che Liu
rClinical Research Centre, Taipei Medical University Hospital, Taipei, Taiwan
sSchool of Dental Technology, College of Oral Medicine
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yu-Lin Lee
tDepartment of Internal Medicine, Changhua Christian Hospital, Changhua, Taiwan
uProgram in Medical Biotechnology, National Chung Hsing University, Taichung, Taiwan
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
I-Chen Tai
cMedigen Vaccine Biologics, Taipei, Taiwan
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Josue Antonio Garcia Estrada
cMedigen Vaccine Biologics, Taipei, Taiwan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Josue Antonio Garcia Estrada
Tzou-Yien Lin
nCollege of Medicine, Chang Gung University, Taoyuan, Taiwan
vDepartment of Paediatrics, Chang Gung Memorial Hospital, Taoyuan, Taiwan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wen-Sen Lee
wDivision of Infectious Disease, Department of Internal Medicine, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan
xDepartment of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: 89425{at}w.tmu.edu.tw
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Objectives To provide data on the immune response to COVID-19 vaccines in people living with HIV (PWH), MVC-COV1901, a recombinant protein vaccine containing S-2P protein adjuvanted with CpG 1018 and aluminium hydroxide, was assessed.

Methods A total of 57 PWH of ≥ 20 years of age who are on stable antiretroviral therapy and with CD4+ T cell ≥ 350 cells/mm3 and HIV viral load < 103 copies/ml were compared with 882 HIV-negative participants. Participants received 2 doses of MVC-COV1901 28 days apart. Safety and the immunogenicity were evaluated.

Results No vaccine-related serious adverse events (SAEs) were recorded. Seroconversion rates (SCRs) of 100% and 99.8% were achieved in people living with HIV (PWH) and comparators, respectively, 28 days after second dose. The geometric mean titers (GMTs) (95% confidence interval [CI]) against wild type SARS-CoV-2 virus were 136.62 IU/mL (WHO Standardized International Unit) (95% CI 114.3-163.3) and 440.41 IU/mL (95% CI 421.3-460.4), for PWH and control groups, respectively, after adjusting for sex, age, BMI category, and comorbidity, and the adjusted GMT ratio of comparator/PWH was 3.22 (95% CI 2.6-4.1). A higher CD4/CD8 ratio was associated with a higher GMT (R=0.27, p=0.039).

Conclusions MVC-COV1901 has shown robust safety but weaker immunogenicity responses in PWH. As a result, a third dose or booster doses of MVC-COV1901 may be appropriate for PWH.

Competing Interest Statement

Chia En Lien, Josue Antonio Garcia Estrada and I-Chen Tai are employees of Medigen Vaccine Biologics (Taipei, Taiwan) and they received grants from Taiwan Centres for Disease Control, Ministry of Health and Welfare, during the conduct of the study. All other authors declare no competing interests.

Clinical Trial

NCT04695652

Funding Statement

The study was funded by Medigen Vaccine Biologics (study sponsor), the Taiwan Centers for Disease Control and Ministry of Health and Welfare.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The trial protocol and informed consent form were reviewed and approved by the ethics committees at the participating sites. The main institutional review board was Chang Gung Medical Foundation (Taoyuan, Taiwan), and other institutional review boards were the following institutes in Taiwan: National Taiwan University Hospital (Taipei), Taipei Veterans General Hospital (Taipei), Tri-Service General Hospital (Taipei), Taipei Medical University Hospital (Taipei), Taipei Municipal Wanfang Hospital (Taipei), Taoyuan General Hospital Ministry of Health and Welfare (Taoyuan), China Medical University Hospital (Taichung), Changhua Christian Hospital (Changhua County), National Cheng Kung University Hospital (Tainan), and Kaoshiung Medical University Chung-Ho Memorial Hospital (Kaoshiung). The trial was done in accordance with the principles of the Declaration of Helsinki and good clinical practice guidelines.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

Data sharing is not applicable to this Article, as it is an interim analysis of data from an ongoing study.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Back to top
PreviousNext
Posted December 09, 2021.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Safety and Immunogenicity of SARS-CoV-2 S-2P Protein Vaccine MVC-COV1901 in People Living with HIV
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Safety and Immunogenicity of SARS-CoV-2 S-2P Protein Vaccine MVC-COV1901 in People Living with HIV
Shu-Hsing Cheng, Chia En Lien, Szu-Min Hsieh, Chien-Yu Cheng, Wang-Da Liu, Ching-Lung Lo, Wen-Chien Ko, Yen-Hsu Chen, Ching-Tai Huang, Hsiao-Ting Chang, Shinn-Jang Hwang, Ning-Chi Wang, Ming-Che Liu, Yu-Lin Lee, I-Chen Tai, Josue Antonio Garcia Estrada, Tzou-Yien Lin, Wen-Sen Lee
medRxiv 2021.12.08.21267439; doi: https://doi.org/10.1101/2021.12.08.21267439
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Safety and Immunogenicity of SARS-CoV-2 S-2P Protein Vaccine MVC-COV1901 in People Living with HIV
Shu-Hsing Cheng, Chia En Lien, Szu-Min Hsieh, Chien-Yu Cheng, Wang-Da Liu, Ching-Lung Lo, Wen-Chien Ko, Yen-Hsu Chen, Ching-Tai Huang, Hsiao-Ting Chang, Shinn-Jang Hwang, Ning-Chi Wang, Ming-Che Liu, Yu-Lin Lee, I-Chen Tai, Josue Antonio Garcia Estrada, Tzou-Yien Lin, Wen-Sen Lee
medRxiv 2021.12.08.21267439; doi: https://doi.org/10.1101/2021.12.08.21267439

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • HIV/AIDS
Subject Areas
All Articles
  • Addiction Medicine (349)
  • Allergy and Immunology (668)
  • Allergy and Immunology (668)
  • Anesthesia (181)
  • Cardiovascular Medicine (2648)
  • Dentistry and Oral Medicine (316)
  • Dermatology (223)
  • Emergency Medicine (399)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (942)
  • Epidemiology (12228)
  • Forensic Medicine (10)
  • Gastroenterology (759)
  • Genetic and Genomic Medicine (4103)
  • Geriatric Medicine (387)
  • Health Economics (680)
  • Health Informatics (2657)
  • Health Policy (1005)
  • Health Systems and Quality Improvement (985)
  • Hematology (363)
  • HIV/AIDS (851)
  • Infectious Diseases (except HIV/AIDS) (13695)
  • Intensive Care and Critical Care Medicine (797)
  • Medical Education (399)
  • Medical Ethics (109)
  • Nephrology (436)
  • Neurology (3882)
  • Nursing (209)
  • Nutrition (577)
  • Obstetrics and Gynecology (739)
  • Occupational and Environmental Health (695)
  • Oncology (2030)
  • Ophthalmology (585)
  • Orthopedics (240)
  • Otolaryngology (306)
  • Pain Medicine (250)
  • Palliative Medicine (75)
  • Pathology (473)
  • Pediatrics (1115)
  • Pharmacology and Therapeutics (466)
  • Primary Care Research (452)
  • Psychiatry and Clinical Psychology (3432)
  • Public and Global Health (6527)
  • Radiology and Imaging (1403)
  • Rehabilitation Medicine and Physical Therapy (814)
  • Respiratory Medicine (871)
  • Rheumatology (409)
  • Sexual and Reproductive Health (410)
  • Sports Medicine (342)
  • Surgery (448)
  • Toxicology (53)
  • Transplantation (185)
  • Urology (165)